Amygdala Scientific Secures Series A Funding Led by XiaChuang Venture Capital to Advance Brain-Computer Interface and Neuromodulation Platforms

Recently, according to Qichacha, AMYGDALA NEURO has completed its Series A financing round, with the investor being Hubei Xiachuang Venture Capital Investment Fund Partnership (Limited Partnership) (referred to as "Xiachuang Ventures"). Reports indicate that, by contributing a subscribed capital amount of 9.62 million yuan, they have acquired 7.4% of the company’s shares, implying a post-investment valuation of approximately 130 million yuan.

At the same time, the company's registered capital has increased significantly from over 80.59 million yuan to nearly 130 million yuan, with an increase of more than 60%.

Notably, the investors in this round of financing are also highly reputable. Xiachuang Venture Capital, established in 2017, is the first state-owned private equity fund manager in Jiangxia District. It manages Jiangxia District's "1+5" government investment fund and has formed a parallel model of "fund + direct investment," with a total scale of 20 billion yuan for the parent fund.

As of now, the scale of 13 sub-funds involved in investment exceeds 30 billion yuan. AMYGDALA NEURO was founded in October 2022, with its headquarters located in Pingshan District, Shenzhen. It is a medical device enterprise guided by clinical needs and focused on developing next-generation neuro-modulation and brain-computer interface technologies and products. The company was spun off from Yingmai Medical and now has a cross-disciplinary R&D team with deep technical backgrounds in mechanics, electronics, software, chips, systems, and science.

Among them, RuiLin Zhao, CEO of AMYGDALA NEURO, graduated from the Young Talent Class (Class of 1986) in Bioengineering at Xi'an Jiaotong University. He later pursued further studies in the United States, obtaining a Master’s degree in Electrical Engineering and Computer Science from MIT, a Ph.D. in Medical Engineering and Medical Physics from the joint program of Harvard University and MIT, and an MBA from the Wharton School of the University of Pennsylvania.

Founder and CEO of AMYGDALA NEURO, Zhao Ruilin, has previously held senior executive positions at renowned companies such as Illumina, Thermo Fisher, MicroPort, Johnson & Johnson Medical, and Medtronic, accumulating extensive industry and management experience. Additionally, he served as an investment partner at CD Capital, gaining deep insights into capital market operations and business growth strategies. In 2020, Zhao Ruilin founded Yingmai Medical and became its CEO, with the company developing advanced technologies in areas like structural heart disease and peripheral vascular interventions. Recognizing the opportunities in brain science, Zhao Ruilin incubated AMYGDALA NEURO within Yingmai Medical, focusing on neuromodulation and invasive brain-computer interfaces.

Another star member of the team, Dr. Min Xiaoyi, CTO of AMYGDALA NEURO, graduated from Sichuan University and holds a Ph.D. from Michigan State University. With over 30 years of experience in the research and development of neuromodulation and cardiac rhythm management products at the U.S. headquarters of Medtronic and Abbott, he owns more than 160 patents. AMYGDALA NEURO’s technology pipeline in the field of brain science medical devices mainly consists of two platforms: the neuromodulation technology platform and the interventional brain-computer interface platform. These encompass innovative technologies such as self-developed chips, precision electrode design and manufacturing, closed-loop algorithms, and MRI compatibility. Based on these, the company has rapidly developed its first batch of products targeting multiple indications including Parkinson's disease, epilepsy, sleep apnea, and spinal cord injury. Several of these products have entered clinical or animal trial stages.

In addition, the company has launched its self-developed dedicated chip AN_ASIC_01, which features 16-channel independent output, ultra-low power consumption, and expandable to higher channels, providing a "Made-in-China chip" solution for brain-computer interfaces and neuromodulation.

Currently, the company has built a full-stack product matrix covering high-throughput research to clinical auxiliary diagnosis. Compared with traditional EEG devices, it offers three differentiated values: closed-loop intervention integrating acquisition and stimulation, an open and interconnected research ecosystem, and future-oriented scalability. With its solid technical capabilities, AMYGDALA NEURO has also repeatedly gained capital favor.

According to Qichacha, the company has completed three rounds of financing: an angel round exceeding 100 million yuan in 2023, an angel+ round in 2024, and this Series A round. These rounds have attracted investments from well-known institutions such as Lilly Asia Ventures, Bangqin Capital, New Industries, CD Capital, AMYGDALA NEURO, 1896 Capital, and楹联Health. The continued investment by multiple industry capitals in this round also demonstrates the high expectations of the capital market for the technological implementation in this sector.

Overall, 2026 marks the first time that brain-computer interfaces (BCIs) have been included in the government work report, officially becoming part of the key future industries nurtured by the state. Driven by both policy and capital, the industry’s development is accelerating from fundamental research towards clinical transformation and large-scale implementation, with its ultimate goal being to address critical clinical challenges. Companies like AMYGDALA NEURO are expected to reshape the diagnosis and treatment pathways for neurological disorders and provide essential equipment support for hospitals to establish BCI-specialized wards. However, for these high-precision devices to move from prototypes to mass production, and from exhibition halls to hospital departments, the collaborative maturation of upstream components such as chips, cables, biomaterials, and other supply chain elements is indispensable. After all, building a vertically integrated BCI industrial ecosystem has become an unavoidable step for the entire industry as it moves toward the mass production phase.